Sandbox Reserved 1660

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 15: Line 15:
== Function ==
== Function ==
-
[[Image:CD1d dependent lipid antigen presentation.jpg | thumb ||left|200px|'''CD1d dependent lipid antigen presentation.''']]
+
[[Image:CD1d dependent lipid antigen presentation.jpg | thumb ||left|190px|'''CD1d dependent lipid antigen presentation.''']]
==== Role in the immune system ====
==== Role in the immune system ====
Line 22: Line 22:
'''CD1d protein''' is a molecule of the [https://en.wikipedia.org/wiki/Immune_system immune system]. It is involved in presenting a lipid antigen to NKT cells. Indeed, these proteins are located on the surface of the plasma membrane of [https://en.wikipedia.org/wiki/Antigen-presenting_cell APC cells]. When the recognition between the CD1d bound to its lipid ligand and the [[TCR]] of a NKT cell occurs, the [https://en.wikipedia.org/wiki/Lymphocyte lymphocyte] turns out to be activated. Thus, the production of cytotoxic molecules such as Th1, Th2, [[interleukin]]-4 and [https://en.wikipedia.org/wiki/Interferon_gamma INF-gamma] is triggered by this activation<ref>Joyce, S. CD1d and Natural T Cells: How Their Properties Jump-Start the Immune System. CMLS, Cell. Mol. Life Sci. 2001, 58 (3), 442–469. https://doi.org/10.1007/PL00000869.</ref><ref name="affinity">Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328.</ref>. Therefore, CD1d proteins are precursors of the adaptive immune reaction which are key activators of the NKT cells. As a result, a deficiency of CD1d proteins may lead to a deficiency of the NKT cells functioning and thus to [https://en.wikipedia.org/wiki/Autoimmune_disease autoimmune diseases] and [https://en.wikipedia.org/wiki/Cancer cancers].
'''CD1d protein''' is a molecule of the [https://en.wikipedia.org/wiki/Immune_system immune system]. It is involved in presenting a lipid antigen to NKT cells. Indeed, these proteins are located on the surface of the plasma membrane of [https://en.wikipedia.org/wiki/Antigen-presenting_cell APC cells]. When the recognition between the CD1d bound to its lipid ligand and the [[TCR]] of a NKT cell occurs, the [https://en.wikipedia.org/wiki/Lymphocyte lymphocyte] turns out to be activated. Thus, the production of cytotoxic molecules such as Th1, Th2, [[interleukin]]-4 and [https://en.wikipedia.org/wiki/Interferon_gamma INF-gamma] is triggered by this activation<ref>Joyce, S. CD1d and Natural T Cells: How Their Properties Jump-Start the Immune System. CMLS, Cell. Mol. Life Sci. 2001, 58 (3), 442–469. https://doi.org/10.1007/PL00000869.</ref><ref name="affinity">Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328.</ref>. Therefore, CD1d proteins are precursors of the adaptive immune reaction which are key activators of the NKT cells. As a result, a deficiency of CD1d proteins may lead to a deficiency of the NKT cells functioning and thus to [https://en.wikipedia.org/wiki/Autoimmune_disease autoimmune diseases] and [https://en.wikipedia.org/wiki/Cancer cancers].
</p>
</p>
 +
<br>
==== Ligands presented by CD1d ====
==== Ligands presented by CD1d ====
Line 28: Line 29:
The ligands that can be presented by CD1d to NKT or other CD1d-restricted T cells are very specific. Only a narrow set of molecules can bind its recognition site. Thus, it limits the risk of other similar molecules or binding CD1d proteins and ensures that the immune response is accurate. Among these molecules are included glycolipids from a marine sponge, bacterial glycolipids, normal endogenous glycolipids, tumor-derived phospholipids and glycolipids, and nonlipidic molecules<ref name="Immunity">Brutkiewicz, R. R. CD1d Ligands: The Good, the Bad, and the Ugly. The Journal of Immunology 2006, 177 (2), 769–775. https://doi.org/10.4049/jimmunol.177.2.769.</ref>.
The ligands that can be presented by CD1d to NKT or other CD1d-restricted T cells are very specific. Only a narrow set of molecules can bind its recognition site. Thus, it limits the risk of other similar molecules or binding CD1d proteins and ensures that the immune response is accurate. Among these molecules are included glycolipids from a marine sponge, bacterial glycolipids, normal endogenous glycolipids, tumor-derived phospholipids and glycolipids, and nonlipidic molecules<ref name="Immunity">Brutkiewicz, R. R. CD1d Ligands: The Good, the Bad, and the Ugly. The Journal of Immunology 2006, 177 (2), 769–775. https://doi.org/10.4049/jimmunol.177.2.769.</ref>.
</p>
</p>
 +
<br>
== Structure ==
== Structure ==
- 
<p align="justify">
<p align="justify">
CD1d protein is made of 2 chains<ref name="Structure">Information, N. C. for B.; Pike, U. S. N. L. of M. R.; BethesdaMD; 20894USA. 3GMQ: Structure of mouse CD1d expressed in SF9 cells, no ligand added https://www.ncbi.nlm.nih.gov/Structure/pdb/3GMQ (accessed Dec 5, 2020).</ref>: <br>
CD1d protein is made of 2 chains<ref name="Structure">Information, N. C. for B.; Pike, U. S. N. L. of M. R.; BethesdaMD; 20894USA. 3GMQ: Structure of mouse CD1d expressed in SF9 cells, no ligand added https://www.ncbi.nlm.nih.gov/Structure/pdb/3GMQ (accessed Dec 5, 2020).</ref>: <br>
-
::- an <scene name='86/868193/Alpha_chain/3'>alpha chain</scene> (T-cell surface glycoprotein CD1d1) of 287 amino acids <br>
+
:- an <scene name='86/868193/Alpha_chain/4'>alpha chain</scene> (T-cell surface glycoprotein CD1d1) of 287 amino acids <br>
-
::- a <scene name='86/868193/Beta-2-microglobulin_chain/2'>beta-2-microglobulin chain</scene> of 99 amino acids. <br><br>
+
:- a <scene name='86/868193/Beta-2-microglobulin_chain/3'>beta-2-microglobulin chain</scene> of 99 amino acids. <br><br>
The first chain is made of two [https://en.wikipedia.org/wiki/Beta_sheet beta-sheets] and a set of 2 [[alpha helix]]. Each beta-sheet contains four antiparallel strands. The total molecular weight of the alpha chain is 33 kDa when not associated to any oligosaccharide and 55 kDa when the five oligosaccharides are associated to the chain.
The first chain is made of two [https://en.wikipedia.org/wiki/Beta_sheet beta-sheets] and a set of 2 [[alpha helix]]. Each beta-sheet contains four antiparallel strands. The total molecular weight of the alpha chain is 33 kDa when not associated to any oligosaccharide and 55 kDa when the five oligosaccharides are associated to the chain.
The ligand binds between the two alpha-helices.
The ligand binds between the two alpha-helices.
Line 41: Line 42:
<p align="justify">
<p align="justify">
-
Additionally, there are two <scene name='86/868193/Oligosaccharides/1'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/1'>site</scene> is located at the A and F pockets in the region of the alpha helices<ref name="site">Schiefner, A.; Fujio, M.; Wu, D.; Wong, C.-H.; Wilson, I. A. Structural Evaluation of Potent NKT-Cell Agonists: Implications for Design of Novel Stimulatory Ligands. J Mol Biol 2009, 394 (1), 71–82. https://doi.org/10.1016/j.jmb.2009.08.061</ref>.
+
Additionally, there are two <scene name='86/868193/Oligosaccharides/2'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/2'>site</scene> is located at the A and F pockets in the region of the alpha helices<ref name="site">Schiefner, A.; Fujio, M.; Wu, D.; Wong, C.-H.; Wilson, I. A. Structural Evaluation of Potent NKT-Cell Agonists: Implications for Design of Novel Stimulatory Ligands. J Mol Biol 2009, 394 (1), 71–82. https://doi.org/10.1016/j.jmb.2009.08.061</ref>.
</p>
</p>
Line 51: Line 52:
NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR<ref name="affinity"/><ref name="site"/>.
NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR<ref name="affinity"/><ref name="site"/>.
</p>
</p>
-
<scene name='86/868193/Morph_3gmq_4f7c_u4681/1'>Conformational variations</scene> between CD1d no ligand and structure of bovine CD1d with bound C12-di-sulfatide.
+
<scene name='86/868193/Morph_3gmq_4f7c_u4681/2'>Conformational variations</scene> between CD1d no ligand and structure of bovine CD1d with bound C12-di-sulfatide.
==== CD1d affinity ====
==== CD1d affinity ====

Revision as of 19:13, 12 February 2021

This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Structure of mouse CD1d expressed in SF9 cells, no ligand added (PDB entry : 3GMQ)

Drag the structure with the mouse to rotate
Personal tools